No Easy Answers for Breast Cancer Gene Testing
|
By LabMedica International staff writers Posted on 18 Jan 2010 |
A genetic mutation can significantly increases a woman's risk of developing breast cancer and ovarian cancer. But does that mean everyone should be tested? A new direct-to-consumer advertising campaign in select markets in the United States urges women to be tested. However, some experts warn that the test is not appropriate for all women.
"While the test is a very easy thing to do--it's a simple blood test --the interpretation of the results can sometimes be very complicated,” said Mark Pearlman, M.D., vice chair and professor of obstetrics and gynecology at the University of Michigan (U-M) Medical School (Ann Arbor, USA).
In fact, experts estimate only 2% of the population should be tested for these mutations, which occur in BRCA1 or BRCA2 genes. Women who inherit a mutation in these genes face a higher lifetime risk of developing breast and ovarian cancer, and cancer is more likely to develop at an earlier age. Lifetime risk of breast cancer in these women jumps from 12.5% in the general population to approximately 60% in women with BRCA mutations. Lifetime ovarian cancer risk rises from 1.4% to 40% for those with the mutation.
But most breast and ovarian cancers are random, and are not linked to the BRCA genes. Fewer than 10% of all women with breast cancer carry one of the BRCA gene mutations, and about 15% of women with ovarian cancer carry one of the mutations. "It's very important that the right women seek out genetic testing for breast and ovarian cancer,” said Sofia Merajver, M.D., Ph.D., director of the Breast and Ovarian Risk Evaluation Program at the University of Michigan Comprehensive Cancer Center. "Cancer risk is more complex than a simple yes or no, and the test for genetic mutations is only part of the picture.”
Women who seek genetic testing should work with a genetic counselor and a physician who is specially trained to help people understand what their test results mean for their cancer risk--and what they can do to reduce that risk. "Working with a genetic counselor, somebody who understands genetics, is very important because a positive test has a plan that has to go with it. At the same time, a negative test doesn't always mean that person is no longer at risk. So getting the test results back without any other knowledge and without any other information is potentially dangerous,' Dr. Pearlman remarked.
Dr. Pearlman and Dr. Merajver work together at the U-M Comprehensive Cancer Center to manage women who are seeking or have undergone genetic testing for breast and ovarian cancer, educating women and their families through genetic counseling, and providing prevention, risk management, and coping strategies for women who test positive. "It's important to understand that getting the genetic test result is only a piece of the puzzle. It really takes a professional who understands genetics to help work with individual women and men to allow them to understand exactly what that piece of information means to them in terms of their risk, their loved ones' risks and what can then be done to help lower that risk,” Dr. Pearlman commented.
For women who do test positive for a mutation, Dr. Pearlman's clinic helps them decide what to do about it. Options include getting mammograms at a younger age or more frequently, using breast magnetic resonance imaging (MRI), taking medication to reduce risk, or making lifestyle changes. Women who are finished with childbearing typically have their ovaries removed, and women may also choose to have their breasts removed to limit their risk.
Doctors recommend genetic testing for those who have: high numbers of family members with cancer diagnoses throughout several generations, either maternal or paternal; family member diagnosed with cancer before age 50; family members who have been diagnosed with multiple cancers (for example, breast and ovarian); and male breast cancers, or clusters of other cancers such as colon, prostate, stomach, or pancreatic.
Related Links:
University of Michigan Medical School
"While the test is a very easy thing to do--it's a simple blood test --the interpretation of the results can sometimes be very complicated,” said Mark Pearlman, M.D., vice chair and professor of obstetrics and gynecology at the University of Michigan (U-M) Medical School (Ann Arbor, USA).
In fact, experts estimate only 2% of the population should be tested for these mutations, which occur in BRCA1 or BRCA2 genes. Women who inherit a mutation in these genes face a higher lifetime risk of developing breast and ovarian cancer, and cancer is more likely to develop at an earlier age. Lifetime risk of breast cancer in these women jumps from 12.5% in the general population to approximately 60% in women with BRCA mutations. Lifetime ovarian cancer risk rises from 1.4% to 40% for those with the mutation.
But most breast and ovarian cancers are random, and are not linked to the BRCA genes. Fewer than 10% of all women with breast cancer carry one of the BRCA gene mutations, and about 15% of women with ovarian cancer carry one of the mutations. "It's very important that the right women seek out genetic testing for breast and ovarian cancer,” said Sofia Merajver, M.D., Ph.D., director of the Breast and Ovarian Risk Evaluation Program at the University of Michigan Comprehensive Cancer Center. "Cancer risk is more complex than a simple yes or no, and the test for genetic mutations is only part of the picture.”
Women who seek genetic testing should work with a genetic counselor and a physician who is specially trained to help people understand what their test results mean for their cancer risk--and what they can do to reduce that risk. "Working with a genetic counselor, somebody who understands genetics, is very important because a positive test has a plan that has to go with it. At the same time, a negative test doesn't always mean that person is no longer at risk. So getting the test results back without any other knowledge and without any other information is potentially dangerous,' Dr. Pearlman remarked.
Dr. Pearlman and Dr. Merajver work together at the U-M Comprehensive Cancer Center to manage women who are seeking or have undergone genetic testing for breast and ovarian cancer, educating women and their families through genetic counseling, and providing prevention, risk management, and coping strategies for women who test positive. "It's important to understand that getting the genetic test result is only a piece of the puzzle. It really takes a professional who understands genetics to help work with individual women and men to allow them to understand exactly what that piece of information means to them in terms of their risk, their loved ones' risks and what can then be done to help lower that risk,” Dr. Pearlman commented.
For women who do test positive for a mutation, Dr. Pearlman's clinic helps them decide what to do about it. Options include getting mammograms at a younger age or more frequently, using breast magnetic resonance imaging (MRI), taking medication to reduce risk, or making lifestyle changes. Women who are finished with childbearing typically have their ovaries removed, and women may also choose to have their breasts removed to limit their risk.
Doctors recommend genetic testing for those who have: high numbers of family members with cancer diagnoses throughout several generations, either maternal or paternal; family member diagnosed with cancer before age 50; family members who have been diagnosed with multiple cancers (for example, breast and ovarian); and male breast cancers, or clusters of other cancers such as colon, prostate, stomach, or pancreatic.
Related Links:
University of Michigan Medical School
Latest Molecular Diagnostics News
- New Library Normalization and Amplification Tools Support Oncology Sequencing
- Ultrasensitive HPV Blood Test Predicts Early Recurrence in Head and Neck Cancer
- Statistical Method Improves Detection of Low-Level Cancer DNA in Blood Samples
- AI Tool Improves Accuracy of Cancer Liquid Biopsy for Therapy Selection
- Targeted RNA Test Enhances Genetic Diagnosis in Exome Sequencing
- Blood Test Predicts Immunotherapy Response in Head and Neck Cancer
- Study Highlights Inherited Breast Cancer Risk Genes in Young Black Women
- New PCR Assay Supports Bundibugyo Ebola Outbreak Surveillance
- Blood-Based RNA Test May Predict Chemotherapy Sensitivity in Lung Cancer
- Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
- Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
- Researchers Uncover Distinct Chromosome Signature in Aggresive ALT Cancers
- Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
- Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
- Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
- Tumor Mutation Marker Helps Refine Lung Cancer Prognosis and Guide Therapy Selection
Channels
Clinical Chemistry
view channel
Simple Blood-Based Cholesterol Efflux Assay Identifies High-Risk Coronary Plaque Features
Unstable coronary plaques are difficult to identify before they trigger acute cardiovascular events. Standard high-density lipoprotein (HDL) measurements do not always capture how well HDL particles function... Read more
Plasma Vitamin C Levels Associated with Brain Structure and Connectivity in Aging
Previous studies have linked vitamin C–rich diets with lower risk of cognitive impairment in older adults. However, few investigations have directly examined blood plasma vitamin C in relation to brain... Read more
Mass Spectrometry Detects Tumor Metabolites for Cancer Monitoring
Cancer’s altered metabolism complicates how clinicians detect and monitor tumors, because nutrient use can shift with context and time. Measuring small-molecule metabolites that distinguish malignant from... Read more
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
Congenital TORCH infections can be asymptomatic during pregnancy yet cause stillbirth, birth defects, and lifelong disability in infants. Many regions still lack robust surveillance to guide testing and... Read more
New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
Clostridioides difficile infections remain a persistent threat in hospitals and communities, affecting about 500,000 people in the United States each year. Severe cases can be fatal within 30 days of diagnosis,... Read morePathology
view channel
Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
Accurate assessment of human epidermal growth factor receptor 2 (HER2) is critical for breast cancer diagnosis and treatment selection, yet scoring variability and infrastructure requirements can complicate... Read more
AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
Accurate classification of brain and spinal cord tumors increasingly depends on molecular profiling alongside histology, but access to such testing remains limited and results can take about two weeks.... Read more
IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
Deficient DNA mismatch repair is an established predictive biomarker for response to immune checkpoint inhibitors, yet access to standardized assessment has varied across tumor types. Cancer remains the... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Open-Source Consortium Aims to Standardize Digital Pathology Workflows
Digital pathology is expanding rapidly as laboratories adopt whole-slide imaging and computational tools to meet growing diagnostic and biomarker-testing demand. However, fragmented software infrastructure... Read more








